UBS Global Healthcare Conference - CLOVER HEALTH INVESTMENTS CORP

Explicit Guidance:

• Financial Performance: Expecting a "strong year of growth" in 2027, building on YTD 2026 performance of $97M adjusted EBITDA and $62M net income; no specific revenue or earnings guidance numbers provided for 2027 due to dynamic growth rates.
• Margins: Projecting "substantial margin expansion" in 2027 driven by cohort maturation; management declines to set a long-term margin target until growth stabilizes, though expects landing in the 2–5% range similar to peers.
• Star Ratings: Confirmed payment economics based on a 4.5-star rating effective for 2027 and trending into 2028.
• Capital: Maintains a strong balance sheet with >$500M in cash/securities and no debt; will fund regulatory capital needs and business investments from 2027 operating cash flow.

Business-Segment Outlook:

• Membership Growth: Anticipating another strong year of membership growth in 2027; new member cohorts are expected to run lower on medical costs than legacy cohorts.
• New Member Mix: Expects ~85% (or potentially higher) of new members in 2027 to be switchers from other Medicare Advantage plans, which historically deliver significantly better Medical Loss Ratios (MLRs) than new enrollees.
• Geographic Expansion: No immediate plans to enter heavily capitated markets like South Florida; expansion strategy targets markets where "Clover Assistant" coverage density can be achieved via employed clinicians (CloverCare Services) or through Counterpart Health partnerships.
• Product Lines:
  • C-SNPs: Actively evaluating entry into Chronic Conditions SNP (C-SNP) markets in 2028+ to leverage Clover Assistant's chronic disease management capabilities; no immediate timeline provided.
  • D-SNPs: No near-term plans to enter Dual Eligible SNP markets due to requirements for Medicaid MCO status in "fifty states" (fully integrated states).
  • Five-Star Contract: Leveraging the five-star rating to drive "incremental enrollments" and growth during the Special Election Period (April–December) in 2027.

Market and Competitive Outlook:

• Share Gains: Expects 2027 growth to be driven by a combination of competitive positioning and a "large plan exit" in core New Jersey market affecting ~40,000 Medicare Advantage members seeking new coverage.
• Pricing Trends: Assumes unit costs and utilization trends similar to national peers on a "factor level," but aggregate trend assumptions may appear lighter due to the mix of new, lower-cost cohorts.
• Competitive Dynamics: Noting a "retreat from $0 PPO" by national MCOs, shifting back to HMO/Value-Based models; views this shift as a market advantage for Clover's PPO product.
• Pharmacy (Part D): Transition to OptumRx in 2027 to actively manage costs and Star Ratings; Part D trends expected to ease relative to 2025 expectations as high trends from the first year of IRA impact subside.

Macro / Industry Outlook:

• Regulation (Risk Adjustment): Cites V28 implementation as a test of agility; confident in reacting to future risk adjustment changes via rapid technology tuning and benefit optimization, similar to the V24–V26 response.
• AI & Technology: Believes AI offers "low-hanging fruit" for SG&A efficiency (member service, claims adjudication, provider payment integrity) and will spread fixed costs as membership scales to 160,000+ lives.
• Economic Environment: Management views the absence of a universal quality bonus as a "relative" playing field; expects normalization through plan design if quality bonuses become universal.

Strategic Initiatives:

• Clover Assistant Expansion: Focus on scaling clinical operations to support 2027 cohort maturation; targeting to extend technology reach beyond the point of care (e.g., ensuring referrals/medication fills occur post-visit).
• Counterpart Health: Near-term goal is to manage as many third-party lives on the platform as Clover Assistant currently manages internally; focused on proving efficacy in new markets before monetizing economics.
• Geographic Replication: Testing entry into new geographies via Counterpart Health to gain "boots on the ground" intel on provider engagement and market dynamics before committing to MA plans.
• PBM Transition: Completed RFP and finalized switch to OptumRx to replace Caremark for 2027 to optimize Part D cost management and Star Ratings.

Risks and Headwinds to Outlook:

• Clinical Operations Scaling: Key risk identified is the ability to scale clinical operations and provider network density in 2027 to support a significantly large new member cohort without diluting Clover Assistant coverage rates.
• New Market Density: Entry into new geographies faces near-term constraints regarding provider panel density; success relies on achieving sufficient Clover MA member volume to incentivize workflow changes among independent physicians.
• AEP Volatility: Final 2027 membership levels and subsequent cash flow/capital needs remain contingent on the outcome of the 2027 Annual Enrollment Period (AEP) and Special Election Period dynamics.
• Retention Dependence: High retention is critical for the cohort maturation story; any headwinds affecting retention or plan design competitiveness could impact earnings expansion.

Management Tone on the Future:

• Confidence: High confidence in 2027 trajectory; describes the current environment as setting up for an "exciting 2027" driven by "strong momentum."
• Differentiation: Repeatedly emphasizes unique agility compared to peers, citing the ability to grow membership and expand margins simultaneously during regulatory shifts (V28).
• Strategic Discipline: Tone suggests a deliberate, data-driven approach to expansion ("you're not going to see us show up in South Florida anytime soon") rather than indiscriminate growth.
• Caveats: No specific quantitative targets provided for 2027 to avoid misalignment with dynamic growth rates; guidance is qualitative, focusing on the drivers (cohort maturation, CA coverage) rather than bottom-line numbers.

Miscellaneous:

• CFO Transition: Clay Thornton has officially transitioned from interim to CFO role.
• Part D Trend Nuance: Part D trends have eased in 2026 relative to 2025 expectations, particularly in non-low-income populations, though outpatient utilization (surgery, ER) is trending higher as inpatient utilization falls.